Tempus xT Hematologic Malignancies DNA Sequencing
Use
Tempus xT Heme offers comprehensive genomic profiling for hematologic malignancies, aiding in diagnosis and risk stratification. This test provides actionable insights by combining clinical and molecular findings, and supplying therapeutic match options based on databases like MSK OncoKB and NCCN Guidelines.
Special Instructions
The test can be ordered standalone or with xR as a combined molecular profiling service. It provides customizable profiling options for patients through Tempus Hub, paper requisition, or EHR integration. Financial assistance is available upon application and evaluation.
Limitations
Validated fusion detection is limited to the analysis of RNA seq data and DNA seq examination of 22 specific genes. Other limitations are not explicitly given; therefore, it is important to interpret results in the context of broader clinical findings.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Not provided.